Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $30.00 Consensus PT from Brokerages

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has earned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $30.00.

Several brokerages have recently commented on KYTX. Wall Street Zen downgraded Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Wednesday, June 24th. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Kyverna Therapeutics in a report on Wednesday, June 3rd. Finally, JPMorgan Chase & Co. decreased their price target on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th.

Kyverna Therapeutics Trading Down 1.1%

NASDAQ:KYTX opened at $7.40 on Monday. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.15 and a quick ratio of 8.15. The firm has a 50-day moving average of $8.38 and a 200-day moving average of $8.56. The company has a market cap of $449.85 million, a PE ratio of -2.26 and a beta of 1.87. Kyverna Therapeutics has a one year low of $2.80 and a one year high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. As a group, equities research analysts expect that Kyverna Therapeutics will post -2.78 EPS for the current fiscal year.

Hedge Funds Weigh In On Kyverna Therapeutics

A number of hedge funds have recently bought and sold shares of the company. AIGH Capital Management LLC raised its holdings in shares of Kyverna Therapeutics by 33.3% in the first quarter. AIGH Capital Management LLC now owns 2,000,000 shares of the company’s stock valued at $17,260,000 after purchasing an additional 500,000 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Kyverna Therapeutics by 16.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,762,617 shares of the company’s stock worth $16,569,000 after purchasing an additional 250,418 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in Kyverna Therapeutics during the fourth quarter worth about $15,667,000. Vanguard Group Inc. boosted its holdings in Kyverna Therapeutics by 0.8% during the third quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company’s stock worth $7,936,000 after purchasing an additional 9,858 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in Kyverna Therapeutics in the 4th quarter worth about $9,220,000. 18.08% of the stock is owned by hedge funds and other institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.